Hemab Therapeutics raises $301.5 million in upsized US IPO
Updated
Updated · Bloomberg · Apr 30
Hemab Therapeutics raises $301.5 million in upsized US IPO
2 articles · Updated · Bloomberg · Apr 30
The Cambridge, Massachusetts-based biotech sold 16.75 million shares at $18 each, the top of its marketed range, exceeding the 15 million shares outlined earlier on Thursday.
Hemab had previously lifted the offering from about 11.8 million shares, with expected net proceeds then estimated at $231.4 million at a $17 midpoint.
The clinical-stage company counts Novo Nordisk Foundation among its biggest investors and will trade on Nasdaq under the ticker COAG.
With a breakthrough drug but no revenue, can Hemab’s upsized IPO deliver on its promise to investors?
As a Boston biotech launches a major IPO, does it signal a true rebound for the life sciences sector?